Develops investigational antibody, enzyme, and siRNA therapies for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, for patients.
10-K for FY2025, filed Feb 25, 2026
Alector has not earned money from product sales; revenue has come mainly from partners licensing and co-developing product candidates. AbbVie payments were spread over the work, while GSK paid an upfront amount for a development license and for research and development services as those services were performed.
10-K for FY2025, filed Feb 25, 2026
$21M
10-K for FY2025, filed Feb 25, 2026
$21M ↗
Biopharmaceutical partners such as GSK and AbbVie have paid Alector under licensing and co-development agreements for product candidates.
10-K for FY2025, filed Feb 25, 2026
No. It lost $142.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
$124.6MView ↗
8-K, filed Jul 8, 2026
Alector, Inc. (the “Company”) was developing the investigational progranulin-elevating monoclonal antibodies, latozinemab and nivisnebart…View ↗
Shrinking. Revenue fell 90% in 4 years, from $207.1M in FY2021 to $21M in FY2025, about 44% a year.
A narrower disease focus
The older report described programs for neurodegenerative diseases and oncology, including immuno-oncology candidates. The latest report focuses its described pipeline on neurodegenerative diseases and brain-delivery programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026The neuroimmune system of the brain is part of the body’s innate immune system, and based on our pioneering work in immuno-neurology, we…View ↗
AL009, is one of our innate immuno-oncology product candidates. AL009 is a multi Siglec inhibitor that is designed to enhance both the…View ↗
AL008 is another of our innate immuno-oncology product candidates. AL008 is an antibody designed to inhibit the CD47-SIRP-alpha (SIRPα)…View ↗
From immune-centered therapies to delivery technology
The older report framed the approach around harnessing the brain’s immune system. The latest report emphasizes targeted mechanisms and its brain-delivery platform across antibodies, enzymes, and siRNA.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026
Competes with Biogen, Eli Lilly, Merck, Roche, and Eisai
10-K for FY2025, filed Feb 25, 2026The biotechnology and pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing…View ↗
Loading...